[HTML][HTML] Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim, BD Young, K Singh… - Nature …, 2022 - nature.com
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim, BD Young… - Nature …, 2022 - econpapers.repec.org
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

[HTML][HTML] Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim, BD Young… - Nature …, 2022 - ncbi.nlm.nih.gov
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in
longstanding sarcoidosis - PMC Back to Top Skip to main content NIH NLM Logo Access …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim, BD Young… - Nature …, 2022 - ui.adsabs.harvard.edu
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim, BD Young… - Nature …, 2022 - ideas.repec.org
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

Inhibition of Type 1 Immunity With Tofacitinib is Associated With Marked Improvement in Longstanding Sarcoidosis

W Damsky, A Wang, DJ Kim… - Nature …, 2022 - digitalcommons.kansascity.edu
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim, BD Young, K Singh… - Nature …, 2022 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Sarcoidosis is an idiopathic inflammatory
disorder that is commonly treated with glucocorticoids. An imprecise understanding of the …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

W Damsky, A Wang, DJ Kim, BD Young… - Nature …, 2022 - europepmc.org
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

W Damsky, A Wang, DJ Kim, BD Young… - Nature …, 2022 - search.ebscohost.com
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …